Elevated circulating fibroblast growth factor 23 is associated with acute kidney injury and mortality in coronavirus disease 2019 (COVID-19).
A blood marker linked to kidney injury and death in COVID-19 patients offers potential for identifying who might benefit from closer monitoring or intervention.
This PubMed record examines Elevated circulating fibroblast growth factor 23 is associated with acute kidney injury and mortality in coronavirus disease 2019 (COVID-19). The abstract's reported finding is: Elevated FGF23 is associated with AKI status and mortality in patients with COVID-19.
What the study was
- Study design
- Prospective observational study
- Population
- Human participants; details in abstract
- Category
- Other
- Maturity
- Exploratory
- Journal
- Jornal brasileiro de nefrologia
Why it surfaced
Retained as a 8/10 high-priority match for Sentinel scan; scoring is conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.